In this role, she found a molecular "signature" in a form of lymphoma that identified patients unlikely to respond well to standard chemotherapy, and who could benefit from treatment with certain experimental targeted drugs.
[3] Following this, Shipp's research team found that serum galectin-1 levels were "significantly associated with tumor burden and additional adverse clinical characteristics in newly diagnosed Hodgkin lymphoma (HL) patients."
[4] In 2014, as chief of the Division of Hematological Neoplasia at Dana-Farber and director of the Lymphoma Program at Dana-Farber/Harvard Cancer Center, Shipp was elected a member of the National Academy of Medicine.
[5] Following her appointment, Shipp and her colleagues led a study on the successfulness of nivolumab, which prompted the Food and Drug Administration to designate it a "breakthrough therapy" for treating relapsed Hodgkin lymphoma.
[8] During the COVID-19 pandemic, Shipp and her colleague Scott J. Rodig earned a Blood Cancer Discoveries Grant to map the immune microenvironment in classical Hodgkin lymphoma.